CTT PHARMACEUTICAL HOLDINGS, INC.
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH): 5 pipeline candidates · 3 upcoming catalysts · ~58 mo cash runway · 5 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
57.8 months
D/E 0.25 · 0% dilution
Lead: Phase 3
5 candidates
3 upcoming, next in ~561d
N/A
A transparent, data-derived signal for CTT PHARMACEUTICAL HOLDINGS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$4.7M
Cash
$32K
Quarterly Burn
$16K
Runway
57.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| abiraterone | Phase 3 |
| androgen deprivation therapy | Phase 3 |
| arn-509 | Phase 3 |
| cannabis based wafer | Preclinical |
| ono-4578 | Phase 1 |
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Frequently asked questions
How many drug candidates are in CTT PHARMACEUTICAL HOLDINGS, INC.'s pipeline?
CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CTT PHARMACEUTICAL HOLDINGS, INC.'s lead drug candidate?
CTT PHARMACEUTICAL HOLDINGS, INC.'s most advanced tracked candidate is abiraterone (Phase 3) for Prostatic Neoplasms.
What is CTT PHARMACEUTICAL HOLDINGS, INC.'s next catalyst?
CTT PHARMACEUTICAL HOLDINGS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivatio" — expected December 31, 2027.
What is CTT PHARMACEUTICAL HOLDINGS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CTT PHARMACEUTICAL HOLDINGS, INC. has approximately 57.8 months of cash runway.
What is CTT PHARMACEUTICAL HOLDINGS, INC.'s market capitalization?
CTT PHARMACEUTICAL HOLDINGS, INC.'s market capitalization is approximately $4.7M.
Get the full picture on CTT PHARMACEUTICAL HOLDINGS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.